PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
20301759-6	1993	MANAGEMENT: Treatment of manifestations: Intramuscular or subcutaneous injections of interferon (IFN)-alpha2a or INF-alpha2b given two or three times a week increase hemoglobin and decrease iron overload in the majority of treated individuals.	Iron	190-194	interferon alpha 17	Homo sapiens	113-122
31995552-5	2020	Conversely, the InfA mRNA allowed ppGpp to compete with GTP for IF2, thus stalling 30S complexes.	Guanosine Triphosphate	56-59	interferon alpha 17	Homo sapiens	16-20
31729458-7	2019	Utilizing pre-ranked GSEA, we showed that primary tumors with Survivors were associated with anti-cancer signaling such as INF-alpha/-gamma response and TNF-alpha signaling, compared with all recurrence groups in pre-ranked GSEA.	gsea	21-25	interferon alpha 17	Homo sapiens	123-132
30701919-5	2018	Sixty three patients were included in the analysis: the first group consisted of 33 patients who received the therapy with ce-pegiterferone alpha-2b (ce-pegalpha-INF-alpha-2b), 10 of them received previous treatment; the second group - 23 patients btained hydroxycarbamide; the third group - 7 patients were treated with recombinant interferon alpha therapy (rINFalpha).	ce-pegiterferone	123-139	interferon alpha 17	Homo sapiens	162-171
30701919-13	2018	Hematologic adverse events (AEs) were more frequently observed in patients receiving ce-pegalpha-INF-alpha-2b therapy.	ce-pegalpha	85-96	interferon alpha 17	Homo sapiens	97-106
28914761-9	2017	We observed that in a dose-dependent manner, silybin and silychristin inhibit the IL-1beta-induced formation of blood platelet-leukocyte aggregates in whole blood samples, as well as the production of pro-inflammatory cytokines-IL-2, TNF, INF-alpha, and INF-gamma.	Silybin	45-52	interferon alpha 17	Homo sapiens	239-248
28914761-9	2017	We observed that in a dose-dependent manner, silybin and silychristin inhibit the IL-1beta-induced formation of blood platelet-leukocyte aggregates in whole blood samples, as well as the production of pro-inflammatory cytokines-IL-2, TNF, INF-alpha, and INF-gamma.	silychristin	57-69	interferon alpha 17	Homo sapiens	239-248
29800615-9	2018	Levels of inflammatory cytokines IL-8, IL-10, IL-6, TNFR2, INF-alpha, and INF-beta were reduced after ruxolitinib treatment.	ruxolitinib	102-113	interferon alpha 17	Homo sapiens	59-68
27495085-13	2016	CONCLUSIONS: PEG-INF-alpha2a plus ADV combination therapy is safe and superior to PEG-INF-alpha2amonotherapyfor decreasing serum HBV DNA and normalizing the ALT level but has no significant impact on the rate of HBeAg seroconversion and HBsAg loss.	Polyethylene Glycols	13-16	interferon alpha 17	Homo sapiens	17-26
26408730-6	2015	In elderly patients treatment with 5-FU plus FA decreased the risk for an event by 1.5-fold compared to 5-FU (HR=0.657, 95%CI=0.495-0.870, p=0.004) and 5-FU plus INFa (HR=0.685, 95%CI=0.515-0.912, p=0.009).	Fluorouracil	35-39	interferon alpha 17	Homo sapiens	162-166
26177560-3	2015	In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin.	Polyethylene Glycols	228-231	interferon alpha 17	Homo sapiens	253-262
26177560-3	2015	In 2009, a genome wide association study (GWAS) revealed that genetic variants in close proximity to the IL28B (IFNL3) gene predicted greater likelihood of achieving sustained virological response (SVR) following treatment with pegylated IFN-alpha (peg INF-alpha) and ribavirin.	Ribavirin	268-277	interferon alpha 17	Homo sapiens	253-262
26177560-4	2015	IL28B (rs12979860 and rs8099917) single nucleotide polymorphisms (SNPs) have been recently found among the Pakistani population associated with response to chronic HCV infection INF-alpha + ribavirin therapy.	Ribavirin	190-199	interferon alpha 17	Homo sapiens	178-187
24293814-4	2012	Results showed that PolyI.C inhibited viral replication, and increased the level of 2",5"-oligoadenylate synthase mRNA transcripts, a marker of INF-alpha/beta induction.	Poly I-C	20-27	interferon alpha 17	Homo sapiens	144-153
17236186-1	2007	A patient with multiple myeloma (MM) was being maintained on human recombinant interferon-alpha (INF-alpha) after VAD and autologous bone marrow transplantation (pretreated with melphalan).	Melphalan	178-187	interferon alpha 17	Homo sapiens	97-106
21569385-8	2011	For further research, we will scrutinize the synergistic effect of active antiviral compound in combination with standard PEG INF-alpha and ribavirin which may be helpful in exploring further gateways for antiviral therapy against HCV.	Polyethylene Glycols	122-125	interferon alpha 17	Homo sapiens	126-135
18300356-6	2008	RESULTS: Sequential lamivudine- INF-alpha therapy, lamivudine and INF-alpha monotherapy reduced ccc DNA of 1.7 log, 1.4 log and 0.8 log, respectively (P < 0.05).	Lamivudine	20-30	interferon alpha 17	Homo sapiens	32-41
18300356-11	2008	CONCLUSION: Forty-eight week sequential lamivudine-INF-alpha therapy and lamivudine monotherapy reduce ccc DNA more significantly than 24-wk INF-alpha monotherapy.	Lamivudine	40-50	interferon alpha 17	Homo sapiens	51-60
21272926-9	2011	While INF-alpha showed only slight enhancement of the cell-death effect of PTX in PTX-sensitive cells, INF-alpha itself strongly induced apoptosis in PTX-resistant cells regardless of PTX concentration.	Paclitaxel	75-78	interferon alpha 17	Homo sapiens	6-15
21272926-11	2011	SP could be a target of INF-alpha, and resistance to PTX might be overcome by INF-alpha.	sp	0-2	interferon alpha 17	Homo sapiens	24-33
21272926-11	2011	SP could be a target of INF-alpha, and resistance to PTX might be overcome by INF-alpha.	Paclitaxel	53-56	interferon alpha 17	Homo sapiens	78-87
20206653-5	2010	However, only cleavable siRNA-PEG conjugates significantly reduced the extent of INF-alpha release as compared to noncleavable siRNA-PEG conjugates, suggesting that they can be potentially used for therapeutic siRNA applications.	Polyethylene Glycols	30-33	interferon alpha 17	Homo sapiens	81-90
19322075-3	2009	Thus, we studied whether human recombinant INF-alpha (rIFN-alpha) would reinstate morphine-conditioned place preference (CPP) in rats.	Morphine	82-90	interferon alpha 17	Homo sapiens	43-52
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	ile184arg	27-36	interferon alpha 17	Homo sapiens	20-26
17331344-2	2007	In the present study, the effects of repeated pre-treatment with recombinant human INF-alpha (rhIFN-alpha) on oral and intravenous pharmacokinetics of a P-gp substrate, docetaxel (DTX; Taxotere) were investigated in a rat model.	Docetaxel	180-183	interferon alpha 17	Homo sapiens	83-92
17331344-2	2007	In the present study, the effects of repeated pre-treatment with recombinant human INF-alpha (rhIFN-alpha) on oral and intravenous pharmacokinetics of a P-gp substrate, docetaxel (DTX; Taxotere) were investigated in a rat model.	Docetaxel	185-193	interferon alpha 17	Homo sapiens	83-92
17454786-5	2007	INF-alpha decreased the colony-forming ability and proliferation of the K562 cells and demonstrated a possibly additive effect with busulfan.	Busulfan	132-140	interferon alpha 17	Homo sapiens	0-9
16622600-5	2006	A PEG(2,40 K) conjugate of INF-alpha-2b exhibited a 330-fold prolonged plasma half life time compared to the native protein.	Polyethylene Glycols	2-5	interferon alpha 17	Homo sapiens	27-36
16041207-2	2005	5-FU cytotoxicity can be modulated by folinic acid (FA) or interferon-alpha (INF-alpha).	Fluorouracil	0-4	interferon alpha 17	Homo sapiens	77-86
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Isoleucine	27-30	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Arginine	33-36	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Isoleucine	64-67	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Arginine	78-81	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Arginine	78-81	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Isoleucine	64-67	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Isoleucine	64-67	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Arginine	78-81	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Isoleucine	64-67	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Arginine	78-81	interferon alpha 17	Homo sapiens	20-26
12490311-4	2003	The distribution of IFNA17 Ile184Arg genotype among SCCA cases (Ile/Ile, 21%; Arg/Ile, 57%; and Arg/Arg, 22%) was different significantly from that among NCC (Ile/Ile, 32%; Arg/Ile, 56%; and Arg/Arg, 12%) (P=0.0345).	Arginine	78-81	interferon alpha 17	Homo sapiens	20-26
10900338-7	2000	These studies show strong structural and functional similarities between INFalpha and opioid peptides, and inferred that the analgesic domain locates around the 122nd Tyr residue of IFNalpha molecule in tertiary structure.	Tyrosine	167-170	interferon alpha 17	Homo sapiens	73-81
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	Dimyristoylphosphatidylcholine	64-94	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	Dimyristoylphosphatidylcholine	96-100	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	dioleyl-phosphatidyl-ethanolamine/dimyristoylphosphatidylcholine	103-167	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	dioleoyl phosphatidylethanolamine	169-173	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	Dimyristoylphosphatidylcholine	174-178	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	dope/dimyristoylphosphatidylglycerol	184-220	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	dioleoyl phosphatidylethanolamine	184-188	interferon alpha 17	Homo sapiens	0-9
15080496-5	2002	INF-alpha was encapsulated in different liposomal formulations, Dimyristoylphosphatidylcholine (DMPC), Dioleyl-phosphatidyl-ethanolamine/Dimyristoylphosphatidylcholine (DOPE/DMPC) and DOPE/Dimyristoylphosphatidylglycerol (DOPE/DMPG).	dimyristoylphosphatidylglycerol	227-231	interferon alpha 17	Homo sapiens	0-9
15080496-12	2002	The results indicate that the MT-IIA mRNA level depends on the liposomal formulation of INF-alpha, and the sustained-time effect of the INF-alpha encapsulated in DMPC liposomes is parallel to that of nonencapsulated INF-alpha over a period of 36 hours.	Dimyristoylphosphatidylcholine	162-166	interferon alpha 17	Homo sapiens	136-145
15080496-12	2002	The results indicate that the MT-IIA mRNA level depends on the liposomal formulation of INF-alpha, and the sustained-time effect of the INF-alpha encapsulated in DMPC liposomes is parallel to that of nonencapsulated INF-alpha over a period of 36 hours.	Dimyristoylphosphatidylcholine	162-166	interferon alpha 17	Homo sapiens	136-145
11899822-7	2002	Three-month INFa treatment lowered levels of TNFa, GM-KSF and CD95+ expression on monocytes as well as TFR-1b concentration in the serum which correlated with a positive trend in the standard clinicolaboratory and virusological indices in the examinees.	gm-ksf	51-57	interferon alpha 17	Homo sapiens	12-16
9180290-1	1997	All-trans retinoic acid (ATRA) has recently been shown to synergize with the inhibitory effect of interferon alpha (IFN alpha) on the growth of malignant cells isolated from solid tumors.	Tretinoin	0-23	interferon alpha 17	Homo sapiens	116-125
11127803-1	1999	The present study was designed to investigate the effect of interferon-alpha ( INF-alpha) on the production of leukotrienes (LTs) and superoxide radicals when intact human neutrophils were stimulated with calcium ionophore (A23187).	Leukotrienes	111-123	interferon alpha 17	Homo sapiens	79-88
11127803-1	1999	The present study was designed to investigate the effect of interferon-alpha ( INF-alpha) on the production of leukotrienes (LTs) and superoxide radicals when intact human neutrophils were stimulated with calcium ionophore (A23187).	Leukotrienes	125-128	interferon alpha 17	Homo sapiens	79-88
11127803-1	1999	The present study was designed to investigate the effect of interferon-alpha ( INF-alpha) on the production of leukotrienes (LTs) and superoxide radicals when intact human neutrophils were stimulated with calcium ionophore (A23187).	Superoxides	134-144	interferon alpha 17	Homo sapiens	79-88
11127803-1	1999	The present study was designed to investigate the effect of interferon-alpha ( INF-alpha) on the production of leukotrienes (LTs) and superoxide radicals when intact human neutrophils were stimulated with calcium ionophore (A23187).	Calcium	205-212	interferon alpha 17	Homo sapiens	79-88
11127803-1	1999	The present study was designed to investigate the effect of interferon-alpha ( INF-alpha) on the production of leukotrienes (LTs) and superoxide radicals when intact human neutrophils were stimulated with calcium ionophore (A23187).	Calcimycin	224-230	interferon alpha 17	Homo sapiens	79-88
11127803-4	1999	Preincubation of intact human neutrophils with INF-alpha and subsequent stimulation with calcium ionophore A23187 also enhanced significantly superoxide radical generation that reduced nitroblue tetrazolium into blue formazan.	Calcimycin	107-113	interferon alpha 17	Homo sapiens	47-56
11127803-4	1999	Preincubation of intact human neutrophils with INF-alpha and subsequent stimulation with calcium ionophore A23187 also enhanced significantly superoxide radical generation that reduced nitroblue tetrazolium into blue formazan.	Superoxides	142-160	interferon alpha 17	Homo sapiens	47-56
9883313-6	1998	The results of the randomized trails, carried out in France, showed that the combination of IFN-alpha and cytarabine as compared with INF-alpha alone, increases the rate of major cytogenetic response and prolongs survival in the chronic phase of CML.	Cytarabine	106-116	interferon alpha 17	Homo sapiens	134-143
10235418-1	1999	Concomitantly we observed an increase of FT4 and FT3 with a totally depressed TSH level 80 days after starting INF-alpha administration.	Thyrotropin	78-81	interferon alpha 17	Homo sapiens	111-120
11127803-4	1999	Preincubation of intact human neutrophils with INF-alpha and subsequent stimulation with calcium ionophore A23187 also enhanced significantly superoxide radical generation that reduced nitroblue tetrazolium into blue formazan.	Nitroblue Tetrazolium	185-206	interferon alpha 17	Homo sapiens	47-56
11127803-4	1999	Preincubation of intact human neutrophils with INF-alpha and subsequent stimulation with calcium ionophore A23187 also enhanced significantly superoxide radical generation that reduced nitroblue tetrazolium into blue formazan.	blue formazan	212-225	interferon alpha 17	Homo sapiens	47-56
11127803-5	1999	The in vivo effect of INF-alpha in rats demonstrated that the higher dose of INF-alpha that induced superoxide radical and LTB4 by A23187 stimulated intact human neutrophil in vitro, also induced a significant decrease in white blood cells and RBCs started at 4 h after i.p administration.	Superoxides	100-110	interferon alpha 17	Homo sapiens	22-31
11127803-5	1999	The in vivo effect of INF-alpha in rats demonstrated that the higher dose of INF-alpha that induced superoxide radical and LTB4 by A23187 stimulated intact human neutrophil in vitro, also induced a significant decrease in white blood cells and RBCs started at 4 h after i.p administration.	Superoxides	100-110	interferon alpha 17	Homo sapiens	77-86
11127803-5	1999	The in vivo effect of INF-alpha in rats demonstrated that the higher dose of INF-alpha that induced superoxide radical and LTB4 by A23187 stimulated intact human neutrophil in vitro, also induced a significant decrease in white blood cells and RBCs started at 4 h after i.p administration.	Calcimycin	131-137	interferon alpha 17	Homo sapiens	77-86
9666567-5	1998	IL-2, IL-3, IL-6, and INF-alpha are able to directly stimulate glucocorticoid production by zona fasciculata and zona reticularis cells, whereas IL-1 exerts an analogous effect through an indirect mechanism involving the stimulation of catecholamine release by chromaffin cells and/or the activation of the intramedullary CRH/ACTH system; again, TNF-alpha depresses glucocorticoid synthesis.	Catecholamines	236-249	interferon alpha 17	Homo sapiens	22-31
9666567-5	1998	IL-2, IL-3, IL-6, and INF-alpha are able to directly stimulate glucocorticoid production by zona fasciculata and zona reticularis cells, whereas IL-1 exerts an analogous effect through an indirect mechanism involving the stimulation of catecholamine release by chromaffin cells and/or the activation of the intramedullary CRH/ACTH system; again, TNF-alpha depresses glucocorticoid synthesis.	chromaffin	261-271	interferon alpha 17	Homo sapiens	22-31
9180290-6	1997	Addition of ATRA to IFN alpha dramatically potentiated the inhibitory effects of INF alpha on CFU-GM growth.	Tretinoin	12-16	interferon alpha 17	Homo sapiens	81-90
9180290-9	1997	RT-PCR analysis of the colonies resulting from the action of the combination IFN alpha plus ATRA showed the presence of an increased number of BCR-ABL-negative colonies relatively to what was observed with IFN alpha alone.	Tretinoin	92-96	interferon alpha 17	Homo sapiens	206-215
9180290-2	1997	We investigated whether ATRA could potentiate the inhibitory effects of IFN alpha on the proliferation of leukemic progenitors in chronic myeloid leukemia (CML).	Tretinoin	24-28	interferon alpha 17	Homo sapiens	72-81
9180290-6	1997	Addition of ATRA to IFN alpha dramatically potentiated the inhibitory effects of INF alpha on CFU-GM growth.	Tretinoin	12-16	interferon alpha 17	Homo sapiens	20-29
1423240-3	1992	This antagonistic effect is paralleled by the ability of tamoxifen to modulate the INF-alpha-induced hyperpolarization in these cells.	Tamoxifen	57-66	interferon alpha 17	Homo sapiens	83-92
8727047-8	1996	Addition of phorbol esters to CHRF-288-11 cells enhances their megakaryocytic phenotype; such treatment also results in increased secretion of INF-alpha, TNF-alpha, and GM-CSF.	Phorbol Esters	12-26	interferon alpha 17	Homo sapiens	143-152
7798436-3	1994	After oral etretinate with a dosage of 50 mg daily was combined with INF-alpha, marked clinical improvement was seen in skin lesions with minor side effects.	Etretinate	11-21	interferon alpha 17	Homo sapiens	69-78
8690043-4	1996	In Northern blot experiments, expression of IL-11 mRNA was reduced in the presence of INF-alpha; this inhibiton was prevented by the addition of cycloheximide.	Cycloheximide	145-158	interferon alpha 17	Homo sapiens	86-95
8179244-6	1993	INF-alpha is also used in histiocytosis X alone or in combination with retinoids or with etoposide and has been found effective in several observations.	Retinoids	71-80	interferon alpha 17	Homo sapiens	0-9
8179244-6	1993	INF-alpha is also used in histiocytosis X alone or in combination with retinoids or with etoposide and has been found effective in several observations.	Etoposide	89-98	interferon alpha 17	Homo sapiens	0-9
8179244-7	1993	In carcinoid syndromes whether treated priorly or not with a 5-fluoro-uracil-streptozoticin combination, INF-alpha leads to an objective response in two-thirds of the patients.	Fluorouracil	61-76	interferon alpha 17	Homo sapiens	105-114
8179244-7	1993	In carcinoid syndromes whether treated priorly or not with a 5-fluoro-uracil-streptozoticin combination, INF-alpha leads to an objective response in two-thirds of the patients.	Streptozocin	77-91	interferon alpha 17	Homo sapiens	105-114
2965208-4	1988	At 300 pM, H2O2-releasing capacity was enhanced 4.4 +/- 1.6-fold over medium control (mean +/- SD for natural INF-alpha, rIFN-alpha A, rIFN-alpha D, and rIFN-beta) compared to an 8.4 +/- 4.8-fold increase with rIFN-gamma (100 pM, 100 U/ml) in the same experiments.	Hydrogen Peroxide	11-15	interferon alpha 17	Homo sapiens	110-119
1906352-6	1991	Thus, the enhanced attachment by primitive CML progenitor cells to INF-alpha-treated stromal cells might be due to changes in the neuraminic acid composition in the stromal cell layer.	Neuraminic Acids	130-145	interferon alpha 17	Homo sapiens	67-76